TY - JOUR
T1 - Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections
AU - Makabenta, Jessa Marie V.
AU - Nabawy, Ahmed
AU - Li, Cheng Hsuan
AU - Schmidt-Malan, Suzannah
AU - Patel, Robin
AU - Rotello, Vincent M.
N1 - Funding Information:
R.P. reports grants from CD Diagnostics, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, ContraFect, TenNor Therapeutics Limited and Shionogi. R.P. is a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics and Qvella; monies are paid to Mayo Clinic. In addition, R.P. has a patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic and a patent on an antibiofilm substance issued. R.P. receives travel reimbursement from the American Society for Microbiology (ASM) and the Infectious Disease Society of America (IDSA), an editor’s stipend from IDSA and honoraria from NBME, Up-to-Date and the Infectious Diseases Board Review Course. All other authors declare no competing interests.
Funding Information:
This research was supported by the US National Institutes of Health (AI134770).
Publisher Copyright:
© 2020, Springer Nature Limited.
PY - 2021/1
Y1 - 2021/1
N2 - Antibiotic-resistant bacterial infections arising from acquired resistance and/or through biofilm formation necessitate the development of innovative ‘outside of the box’ therapeutics. Nanomaterial-based therapies are promising tools to combat bacterial infections that are difficult to treat, featuring the capacity to evade existing mechanisms associated with acquired drug resistance. In addition, the unique size and physical properties of nanomaterials give them the capability to target biofilms, overcoming recalcitrant infections. In this Review, we highlight the general mechanisms by which nanomaterials can be used to target bacterial infections associated with acquired antibiotic resistance and biofilms. We emphasize design elements and properties of nanomaterials that can be engineered to enhance potency. Lastly, we present recent progress and remaining challenges for widespread clinical implementation of nanomaterials as antimicrobial therapeutics.
AB - Antibiotic-resistant bacterial infections arising from acquired resistance and/or through biofilm formation necessitate the development of innovative ‘outside of the box’ therapeutics. Nanomaterial-based therapies are promising tools to combat bacterial infections that are difficult to treat, featuring the capacity to evade existing mechanisms associated with acquired drug resistance. In addition, the unique size and physical properties of nanomaterials give them the capability to target biofilms, overcoming recalcitrant infections. In this Review, we highlight the general mechanisms by which nanomaterials can be used to target bacterial infections associated with acquired antibiotic resistance and biofilms. We emphasize design elements and properties of nanomaterials that can be engineered to enhance potency. Lastly, we present recent progress and remaining challenges for widespread clinical implementation of nanomaterials as antimicrobial therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=85089600634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089600634&partnerID=8YFLogxK
U2 - 10.1038/s41579-020-0420-1
DO - 10.1038/s41579-020-0420-1
M3 - Review article
C2 - 32814862
AN - SCOPUS:85089600634
SN - 1740-1526
VL - 19
SP - 23
EP - 36
JO - Nature Reviews Microbiology
JF - Nature Reviews Microbiology
IS - 1
ER -